医学
回顾性队列研究
心力衰竭
多中心研究
内科学
移植
心脏移植
重症监护医学
心脏病学
随机对照试验
作者
John Louca,Marco Öchsner,S. Bhagra,Ashish Shah,Kelly Schlendorf,Brian Lima,Chen Chia Wang,Hasan K. Siddiqi,Ali Irshad,Jacob Schroder,Sarah Casalinova,Carmelo A. Milano,Kiran K. Khush,A. Skoda,Helen Luikart,Euan A. Ashley,Nader Moazami,Les James,Owais Dar,Mailén Konicoff
标识
DOI:10.1016/j.jchf.2025.04.003
摘要
As donation after circulatory determination of death (DCD) heart transplantation (HT) becomes more widely adopted, there is a need to establish the most clinically effective method of organ procurement. This international, multicenter study compares outcomes of DCD-HT across Europe and the United States (US) between recipients whose donor hearts were retrieved using thoraco-abdominal normothermic regional perfusion (taNRP) to those whose hearts were recovered using direct procurement and perfusion (DPP). This was a retrospective observational study across 20 heart transplant centers in Belgium, Spain, the United Kingdom (UK) and the US. This study included all patients undergoing DCD-HT at participating centers, from the start of each center's DCD program through 01/01/2023. DCD-HT with recovery using either taNRP or DPP were compared to one-another. Post-transplant outcomes included (i)survival at 1-year, (ii)incidence of severe primary graft dysfunction (PGD), (iii)episodes of treated, biopsy-proven acute-cellular rejection (ACR) in the first year following transplantation. 504 DCD-HT took place in the study period. Survival at one year was similar for taNRP and DPP recipients (91% vs 88%, p=0.1). taNRP recipients had a lower rate of severe PGD (7.6% vs 19.2%, p<0.001) and fewer episodes of biopsy-proven, ACR requiring treatment in the first-year post-transplantation (13% vs 25%,p<0.001). In an international study of DCD-HT, recipients of hearts retrieved by taNRP technique had lower rates of severe PGD and fewer episodes of biopsy-proven ACR in the first year when compared with those retrieved utilizing DPP. These results should be further investigated with randomized control trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI